Neoplasms

All Conditions

Rare Diseases

Sarcoma

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Soft Tissue Sarcoma

Antineoplastic Agents

All Drugs and Chemicals

Micronutrients

Temozolomide

Cobalt

Antineoplastic Agents, Alkylating

Alkylating Agents

Proton Chemoradiotherapy followed by surgery. Temozolomide five days per week during radiotherapy for 5 weeks. Proton radiation five days per week for 5 weeks Standard surgery will take place 4-6 weeks after completion of chemoradiation.

Chemoradiotherapy Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks. Temozolomide should be taken orally 1 hour before each session of radiotherapy during weekdays (Monday through Friday). The dose will be determined using the body surface area (BSA) calculated at the beginning of the concurrent treatment. The BSA will be calculated from the height obtained at the pretreatment visit and the weight obtained before the first day of treatment. The concurrent treatment will last until the end of radiotherapy.

50 cobalt gray equivalent(CGE), 25 daily fractions, 5 weeks (2 CGE/fx)

Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks.Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks. Temozolomide should be taken orally 1 hour before each session of radiotherapy during weekdays (Monday through Friday). The dose will be determined using the body surface area (BSA) calculated at the beginning of the concurrent treatment. The BSA will be calculated from the height obtained at the pretreatment visit and the weight obtained before the first day of treatment. The concurrent treatment will last until the end of radiotherapy.

Chemoradiotherapy Temozolomide

Proton therapy

Proton Chemoradiotherapy followed by surgery. Resection of tumor at 4-6 weeks post-treatment.

Proton Chemoradiotherapy followed by surgery

Daniel J Indelicato, MD

The goal of this study is to evaluate the effects of temozolomide and radiation combination in the treatment intended of soft tissue sarcomas.

This study will also look at the tumor tissue that was removed during your initial biopsy and your final surgery for information that may help to treat soft tissue sarcoma in the future. In addition the investigators will examine a sample of your normal tissue (optional) from the inside of your mouth/cheek (to compare it to your tumor tissue) before starting treatment.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas	NCT00881595	Soft Tissue Sar...	Chemoradiothera... Proton therapy Proton Chemorad...	55 Years -	University of Florida
Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas	NCT00881595	Soft Tissue Sar...	Chemoradiothera... Proton therapy Proton Chemorad...	55 Years -	University of Florida

Spots Global Cancer Trial Database for chemoradiotherapy temozolomide